Keynote Speakers

Peter H. Seeberger

Max Planck Institute of Colloids and Iterfaces, Potsdam, Germany
Freie Universität, Berlin, Germany

Synthetic glycans as basis for vaccines, therapeutic antibodies and diagnostics

Stephan Bachmann

F. Hoffmann-La Roche Ltd.,
Basel, Switzerland

Catalysis as key technology for the synthesis and scale-up of APIs and their intermediates

Frank Wagner

Charité, Berlin, Germany

Focus on early clinical trials

Invited Speakers

Daniela Angst

Novartis, Basel, Switzerland

Remibrutinib, a covalent BTK inhibitor with best-in-class selectivity: discovery and clinical results

Roy Bar-Ziv

Weizmann Institute of Science, Rehovot, Israel

"Artificial Cells" on a chip

Martina Benešová-Schäfer

German Cancer Research Center, Heidelberg, Germany

Pharmaceutical radiochemistry in modern nuclear medicine

Andrea Brancale

UCT Prague, Czech Republic

Kick-start new drug design projects using computer-aided drug design

Oliviana Calin-Eller

E. Blum & Co. AG, Zurich, Switzerland

Patents: Why? What? How?

Richard Clarkson

Cardiff University, UK

Targeting cells responsible for metastatic disease

Camille Correia

Merck Electronics KGaA, Darmstadt, Germany

Modular continuous automation for laboratories and production

Deborah Fass

Weizmann Institute of Science, Rehovot, Israel

Structures of mucin glycoproteins inspire molecular methods for modulating mucosal functions

Paulina Kaplonek

Moderna, USA

Identifying the correlates of immunity for better vaccine design

Valery Khrizanovsky

Weizmann Institute of Science, Rehovot, Israel

Senescent cells in aging and age-related disease: the good, the bad and the ugly

Jan Konvalinka

IOCB Prague, Czech Republic

Chemical-biology tools in drug development

Sima Lev

Weizmann Institute of Science, Rehovot, Israel

Triple-negative breast cancer: heterogeneity and targeted therapy

David Margulies

Weizmann Institute of Science, Rehovot, Israel

Detecting proteins and protein-inhibitor interactions with ‘turn-on’ fluorescent molecular probes: design principles and applications in medical diagnosis, cell imaging and drug Discovery

Petra Ménová

UCT Prague, Czech Republic

How are new drugs born?

Johan Neyts

KU Leuven, Belgium

Discovery and development of antiviral drugs

Jitka Palich Fučíková

Sotio Biotech Department of Immunology, 2nd Medical school, Charles University

The role of immune system in cancer therapy

Christoph Rademacher

University of Vienna, Austria

Cell-specific targeted delivery of therapeutics

Pavlína Řezáčová

IOCB Prague, Czech Republic

Structure-assisted design of enzyme inhibitors

Jitka Riedl

Bicycle Therapeutics, Cambridge, UK

Attacking from all angles: EphA2 targeting Bicycle® peptides for precision guided cancer therapy via multiple approaches

Menachem Rubinstein

Weizmann Institute of Science, Rehovot, Israel

Directing viral vectors to specific cell types for oncolytic virotherapy and in vivo gene therapy

Gideon Schreiber

Weizmann Institute of Science, Rehovot, Israel

Reversing protonation of weakly basic drugs greatly enhances intracellular diffusion and decreases lysosomal sequestration

Marek Šťastný

Medical Department, Bristol-Myers Squibb

Cancer immunotherapies based on anti-PD1: clinical perspectives and challenges

Kvido Stříšovský

IOCB Prague, Czech Republic

The elusive mechanisms of unexpected regulators of inflammatory and growth factor signalling

Michal Tichý

IOCB Prague, Czech Republic

Kinase Inhibitors: From insoluble and promiscuous hit to drug candidate

Igor Ulitsky

Weizmann Institute of Science, Rehovot, Israel

Therapeutic targeting of RNA molecules

Kateřina Vávrová

Faculty of Pharmacy Hradec Kralove, Charles University, Czech Republic

Ceramides in the skin: extraordinary lipids for an extraordinary barrier

Milan Vrábel

IOCB Prague, Czech Republic

Chemical engineering of cell surfaces for cancer immunotherapy

Stella Vukelic

AbbVie, Ludwigshafen, Germany

Molecular obesity – An addiction in drug discovery?

Yosef Yarden

Weizmann Institute of Science, Rehovot, Israel

Overcoming resistance of lung cancer to tyrosine kinase inhibitors


May 2024 programme added

March 2024 Best Poster Award
We would like to encourage participants to present their research in the form of a poster presentation. The Scientific Committee will evaluate all contributions and award the BEST POSTER.

scholarship application open

February 2024 online registration open

January 2024 list of speakers added

Second Announcement Flyer

Previous Conferences